XT
KLRS

XTX Topco’s Kalaris Therapeutics KLRS Stock Holding History

XTX Topco’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,897
Closed -$92K – 4559
2025
Q4 		$92K Buy
+10,897
New +$69.7K ﹤0.01% 2659
2025
Q3 		– Sell
-24,234
Closed -$64.7K – 3485
2025
Q2 		$64.7K Buy
+24,234
New +$109K ﹤0.01% 1970
2024
Q4 		– Sell
-1,153
Closed -$21.4K – 3066
2024
Q3 		$21.4K Sell
1,153
-901
-44% -$15.8K ﹤0.01% 1834
2024
Q2 		$34.2K Buy
2,054
+34
+2% +$600 ﹤0.01% 1549
2024
Q1 		$35.1K Sell
2,020
-363
-15% -$5.92K ﹤0.01% 1531
2023
Q4 		$37.3K Sell
2,383
-1,271
-35% -$50.1K 0.01% 1283
2023
Q3 		$181K Buy
+3,654
New +$249K 0.03% 1050
2023
Q2 		– Sell
-848
Closed -$76.9K – 1923
2023
Q1 		$76.9K Sell
848
-1,475
-63% -$188K 0.02% 1128
2022
Q4 		$274K Buy
2,323
+1,627
+234% +$276K 0.06% 646
2022
Q3 		$126K Buy
696
+139
+25% +$21.7K 0.03% 902
2022
Q2 		$50K Buy
+557
New +$58.4K 0.02% 744

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

XTX Topco's KLRS Position: Q1 2026 in Review

XTX Topco sold out of Kalaris Therapeutics (KLRS) in Q1 2026, closing a stake of 10,897 shares — an estimated $92K sold.

XTX Topco first reported a position in KLRS in Q2 2022 and held it in 11 quarters. The position peaked at $274K in Q4 2022. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • XTX Topco reported no remaining Kalaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 10,897 Kalaris Therapeutics shares in Q1 2026, an estimated $92K.
  • XTX Topco first reported a position in Kalaris Therapeutics in Q2 2022 and held it in 11 quarters.
  • XTX Topco's Kalaris Therapeutics position peaked at $274K in Q4 2022.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.